Skip to main content

Table 2 MiRNA expression in good versus poor responders

From: Beyond KRAS mutation status: influence of KRAScopy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients

 

Good responders

Poor responders

RQ Good versus poor

P value

Mean ddCt

SE

RQ

Mean ddCt

SE

RQ

MiR-27b

−0.98

0.77

1.98

−0.92

0.64

1.90

1.04

0.80

MiR-105

−1.04

2.80

2.05

0.57

3.15

0.68

3.01

0.21

MiR-155

−0.66

1.25

1.58

−0.19

0.89

1.14

1.39

0.24

MiR-346

0.32

1.52

0.80

0.57

1.14

0.67

1.19

0.60

MiR-181a

−1.64

0.85

3.11

−1.27

0.75

2.42

1.29

0.21

MiR-19a

−3.39

1.84

10.45

−2.82

1.55

7.04

1.48

0.35

MiR-200b

−0.57

0.92

1.49

0.05

1.42

0.97

1.54

0.15

MiR-27a

−2.10

0.98

4.27

−2.00

0.82

4.00

1.07

0.77

MiR-30a

−0.81

0.86

1.75

−0.66

0.88

1.58

1.11

0.65

Let-7a

−0.67

0.79

1.59

−0.39

0.70

1.31

1.21

0.30

MiR-21

−3.16

1.16

8.92

−2.75

0.79

6.75

1.32

0.26

MiR-96

−4.56

1.32

23.59

−3.81

1.40

14.04

1.68

0.13

MiR-143

−0.73

1.35

1.66

−1.76

1.55

3.38

0.49

0.07

MiR-217

−2.91

3.09

7.53

−1.64

3.10

3.12

2.41

0.30

MiR-133a

0.91

1.69

0.53

0.33

1.79

0.79

0.67

0.36

MiR-133b

0.98

1.74

0.51

0.39

2.23

0.76

0.67

0.41

MiR-19b

−2.95

1.71

7.73

−2.45

1.37

5.45

1.42

0.37

  1. Abbreviations: SE = standard error, RQ = relative quotient.